Work

A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.

Year: 2009

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs-09-5090

Authors: I. Krop, P. LoRusso, K. Miller, S. Modi, D. Yardley, G. Rodriguez, S. Agresta, M. Zheng, L. Amler, H. Rugo

Institutions: Dana-Farber Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2066876982

Cites:

Cited by: 46

Related to: 10